Stanford Seeks 1,000 for New COVID-19 Vaccine Trial

Thanks to KRON4 for letting us know that Stanford is joining the race to find a COVID-19 vaccine.

On Monday, Stanford Medicine announced it has joined a large “Phase 3” clinical trial of an experimental vaccine

Stanford Medicine begins enrolling for COVID-19 vaccine trial

Stanford Medicine has joined a large, Phase 3 clinical trial of an experimental vaccine against COVID-19.

The trial will test whether the vaccine, which is produced by the Janssen Pharmaceutical Companies of Johnson & Johnson, protects people from the disease. It will enroll some 60,000 people at about 180 sites around the world. The Stanford site is expected to enroll about 1,000 participants.  

• Enrollment for COVID-19 Vaccine Trial begins – See if you qualify

Initial Phase 1 and 2 trials of the Janssen vaccine uncovered no major side effects or safety concerns when used in humans, and animal studies suggested that, unlike other vaccine candidates, one dose of the Janssen vaccine was sufficient to trigger a potentially protective immune response.

Read More: Stanford Medicine | Ensemble Study | KRON4